The Fight Over Price Gouging By The Pharmaceutical Industry
By Lydia O'neal And David Sirota for International Business Times - As the Democratic Governors Association raised $2.28 million from drug companies and health insurers in the first half of 2017, the group’s chairman, Connecticut Gov. Dan Malloy, echoed a health care lobbyist’s criticism of a landmark bill to combat drug price-gouging, according to documents obtained by International Business Times. The documents detail how Malloy’s insurance department, led by a former Cigna lobbyist, tried to water down the bipartisan initiative as it moved through the state’s legislature. This spring, while Washington lawmakers wrestled over national health care policy, Connecticut lawmakers worked to join several other states that have passed legislation to curb an alleged drug price fraud scheme at the heart of multiple class-action lawsuits across the country. The suits accuse insurance firms and their pharmacy benefit managers, or PBMs, of attaching arbitrary and fraudulent premiums to consumers’ prescription drug prices, then pocketing the cost difference — all while using “gag orders” to keep pharmacies from informing customers about lower-priced options.